news ES17 phages can destroy bacteria before gut infection in mice 10 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
news Bacteriophage genes could lead to development of new antibiotics 8 February 2021 | By Victoria Rees (Drug Target Review) New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
news Role of retrons in bacteria revealed, with potential for use in gene editing 9 November 2020 | By Victoria Rees (Drug Target Review) The role that retrons in bacteria has been discovered by researchers, who found they protect colonies when infected by viruses.
news Platform for hit-to-lead identification of antibacterial lysins developed 6 October 2020 | By Victoria Rees (Drug Target Review) A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
news Novel CRISPR enzyme could expand the range of targets for gene therapy 20 July 2020 | By Hannah Balfour (Drug Target Review) The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
article Empty phage viruses as a method to combat influenza 26 May 2020 | By Victoria Rees (Drug Target Review) A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
news Novel phage display technique could lead to new peptide-based therapeutics 20 March 2020 | By Hannah Balfour (Drug Target Review) Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
news CRISPR-Cas3 used to combat C. difficile in lab and mice 11 March 2020 | By Victoria Rees (Drug Target Review) Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
news Phage-enriched mucosal surfaces could combat bacteria infections 29 November 2019 | By Victoria Rees (Drug Target Review) Researchers have found that, in rainbow trout models, phages on mucosal surfaces infect pathogenic bacteria, providing protection.
news Phage therapy shows potential to treat alcoholic liver disease 14 November 2019 | By Rachael Harper (Drug Target Review) Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
news Study identifies strain of bacteria as a risk factor for stomach cancer 13 September 2018 | By Drug Target Review Researchers have found a specific strain of Helicobacter pylori strongly correlated with stomach cancer...
news Genetically engineered bacteria show promise as a new treatment for constipation 15 June 2018 | By Drug Target Review Researchers have genetically engineered bacteria as a potential new treatment for constipation, the finding is significant in part because there are few approved constipation remedies on the market...
news Potential targets for treatment of leishmaniasis identified 6 October 2017 | By Dr Zara Kassam (Drug Target Review) Brazilian scientists show that parasite's penetration of host cells increases expression of certain microRNAs capable of inhibiting the action of the immune system...
news University of Leicester gets funding to develop bacteriophages 27 May 2016 | By Victoria White, Digital Content Producer Professor Martha Clokie has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world...
news Pherecydes Pharma appoints Fanneau de La Horie as CEO 22 February 2016 | By Katie Sadler Pherecydes Pharma has announced the appointment of Guy-Charles Fanneau de La Horie, MBA as its new Chief Executive Officer.
